Free Trial
→ Only a handful of people know the setup that's defied these chaotic markets. (From WealthPress) (Ad)
NASDAQ:HEPA

Hepion Pharmaceuticals Q1 2024 Earnings Report

Hepion Pharmaceuticals logo
$0.06 -0.01 (-7.69%)
As of 03:53 PM Eastern
ProfileEarnings History

Hepion Pharmaceuticals EPS Results

Actual EPS
-$28.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hepion Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hepion Pharmaceuticals Announcement Details

Quarter
Q1 2024
Date
5/21/2024
Time
N/A
Conference Call Date
Tuesday, May 21, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Hepion Pharmaceuticals' next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

Powered by Quartr

Earnings Documents

Hepion Pharmaceuticals' Q1 2024 Quarterly reportQuarterly report
(10-Q)

Hepion Pharmaceuticals Earnings Headlines

Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
May 13, 2025 | finanznachrichten.de
Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'
May 13, 2025 | msn.com
This document could hand you a shot at $915 every single weekend!
Something fascinating happens in the options market when most traders aren't paying attention… While everyone else collects standard daily premiums Monday through Friday... There's a special opportunity to target TRIPLE premiums just for holding positions over the weekend. Think about that... Most traders get one day's worth of premium for their trades. But by entering right before the weekend, when everything works out, you could collect THREE days worth - even though markets are closed for two of them. Thanks to a special discovery by a Wall Street legend who helped manage a $1.7 trillion firm – regular folks like you can now target extra cash from the markets on weekends… Just like he showed his small group of traders on December 20th with KO... A quick 2-minute setup Friday afternoon… Head out for the weekend... Monday morning? An extra $1,111 sitting in the account (with a $5k starting stake).
May 29, 2025 | WealthPress (Ad)
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
May 12, 2025 | globenewswire.com
Hepion Pharmaceuticals Enters Binding LOI with New Day Diagnostics for In-Licensing of CE-Marked Diagnostic Tests
May 9, 2025 | nasdaq.com
Hepion Partners With New Day Diagnostics To Commercialize Diagnostic Tests
May 9, 2025 | nasdaq.com
See More Hepion Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hepion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hepion Pharmaceuticals and other key companies, straight to your email.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals (NASDAQ:HEPA), a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

View Hepion Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles